12-24 Hours
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
0 People recently viewed this
Eporise
Ziska Pharmaceuticals Ltd.
Generic: Erythropoietin
Safety Advices
বাংলা
English
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Eporise. Please consult your doctor.
CONSULT YOUR DOCTOR
Eporise may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
SAFE IF PRESCRIBED
Eporise is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
UNSAFE
Eporise may cause side effects which could affect your ability to drive.
SAFE IF PRESCRIBED
Eporise is safe to use in patients with kidney disease. No dose adjustment of Eporise is recommended.
Regular monitoring of kidney function tests is advised while the patient is taking this medicine.
CAUTION
Eporise should be used with caution in patients with liver disease. Dose adjustment of Eporise may be needed. Please consult your doctor.
Medicine Overview of Eporise 5000IU/0.5ml Injection
Introduction
Eporise is a medicine that helps your bone marrow to produce more red blood cells. It is used to treat a type of anemia caused by kidney disease. It is also used to treat anemia caused by cancer chemotherapy and by taking medicines to treat HIV. Eporise is given by injection either under the skin or into a vein which will be decided by your doctor. Usually the injections are given by a nurse or doctor. The dose depends on your body weight and the cause of your anemia. Iron supplements both before and during treatment may make this treatment...
... Show moreUses of Eporise
- Anemia due to chronic kidney disease
- Anemia due to cancer chemotherapy
Side effects of Eporise
Common
- High blood pressure
- Nausea
- Fever
- Vomiting
How to use Eporise
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Eporise works
Eporise is an erythropoiesis-stimulating agent (ESA). It works by stimulating the bone marrow (soft tissue inside the bones which produces red blood cells) to produce more red blood cells.
What if you forget to take Eporise?
If you miss a dose of Eporise, please consult your doctor.
Quick Tips
- Eporise helps in the treatment of anemia that may have occurred due to chronic kidney disease or cancer chemotherapy.
- It is given as a single injection under your skin.
- Your doctor may get your blood tests done regularly to monitor the levels of hemoglobin, blood cells and electrolytes such as potassium in your blood.
- Monitor your blood pressure regularly while taking this medication. Inform your doctor if you notice symptoms of very high blood pressure such as severe headache, problems with your eyesight, nausea, vomiting or fits (seizures).
- Stop taking Eporise and inform your doctor if you develop shortness of breath or skin rash.
Brief Description
Indication
Anemia associated with Chronic Renal Failure, including patients on dialysis (ESRD) and patients not on dialysis, Anemia in patients with non-myeloid malignancies where anemia is due to the effect of concomitantly administered chemotherapy, Anemic patients (hemoglobin > 10 to < 13 g/dL) scheduled to undergo elective, noncardiac, nonvascular surgery to reduce the need for allogeneic blood transfusions, Anemia related to therapy with zidovudine in HIV-infected patients.
Adult Dose
Chronic Kidney Disease-Associated Anemia Reduction of need for red blood cell (RBC) transfusion in patients with chronic kidney disease (CKD) Patient not on dialysis: 50-100 units/kg IV/SC 3 times weekly initially Initiate only when (1) hemoglobin level 10 g/dL, reduce or interrupt dose and use lowest dose sufficient to reduce need for RBC transfusion Patient on dialysis: 50-100 units/kg IV 3 times weekly initially Initiate when hemoglobin level 2 months 150 units/kg IV/SC 3 times weekly initially; alternatively, 40,000 units SC once weekly until completion of chemotherapy course Preparation for Surgery With High Risk of Blood Loss Reduction of need...
... Show moreChild Dose
Chronic Kidney Disease-Associated Anemia
1 month: 50 units/kg IV/SC 3 times weekly initially; if patient on dialysis, IV route recommended
Initiate when hemoglobin level <10 g/dL; if hemoglobin level approaches or exceeds 11 g/dL, reduce or interrupt dose
Prematurity-Related Anemia
25-100 units/kg SC 3 times weekly or 200-400 units/kg SC/IV q24-48hr for 2-6 weeks
Zidovudine-Related Anemia
<8 months: Safety and efficacy not established
8 months-17 years: 50-400 units/kg SC/IV 2-3 times weekly
Chemotherapy-Related Anemia
<5 years: Safety and efficacy not established
5-18 years: 600 units/kg IV once weekly; not to exceed 40,000 units
Contraindication
Uncontrolled hypertension, hypersensitivity to mammalian cell products and human albumin.
Mode of Action
Erythropoietin regulates erythropoiesis by stimulating the differentiation and proliferation of erythroid precursors, stimulating the release of reticulocytes into the circulation, and synthesis of cellular haemoglobin. Recombinant human erythropoietin is available as epoetin alfa and epoetin beta which are used in the management of anaemias associated with CRF, cancer chemotherapy and anti-AIDS drug zidovudine.
Precaution
Erythropoietin should be used with caution in those patients with controlled hypertension, ischaemic vascular disease, history of seizures, or suspected allergy to the product. Iron evaluation: Prior to and during Epoetin therapy, the patient's iron stores, including transferrin saturation and serum ferritin, should be evaluated. Transferrin saturation should be at least 20%, and ferritin should be at least 100 ng/mL. Virtually all patients will require supplemental iron to increase or maintain transferrin saturation to levels that will adequately support erythropoiesis.
Lactation: Unknown whether drug is excreted in breast milk; use with caution; avoid administering multidose vials
Side Effect
>10%
Pyrexia (10-42%),Nausea (11-35%),Hypertension (14-27%),Cough (4-26%),Vomiting (12-28%),Pruritus (12-21%),Rash (2-19%),Headache (5-18%),Arthralgias (10-16%)
1-10%
Arthralgia (10%),Myalgia (10%),Stomatitis (10%),Diarrhea (9%),Dizziness (9%),Edema (9%),Fatigue (9%),Weight decrease (9%),Medical device malfunction (artificial kidney clotting during dialysis) (8%),Vascular occlusion (vascular access thrombosis) (8%),Vomiting (8%),Asthenia (7%),Chest pain (7%),Injection-site irritation (7%),Muscle spasm (7%),Upper respiratory tract infection (URTI) (7%),Urticaria (3%),Seizures (2.5%),Pulmonary embolism (1%),Respiratory tract congestion (1%)
Potentially Fatal: Hypertensive crisis with encephalopathy-like symptoms e.g. headache, confusion, generalised seizures. Thrombosis.
Interaction
Haematinics enhance efficiency. Increased dose of heparin in patients undergoing dialysis.
ব্যবসার জন্য পাইকারি দামে পণ্য কিনতে রেজিস্টেশন করুন
Register
